<?xml version='1.0' encoding='UTF-8' standalone='no'?>
<rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:bqbiol="http://biomodels.net/biology-qualifiers/" xmlns:collex="http://www.collex.org/schema#" xmlns:bqmodel="http://biomodels.net/model-qualifiers/" xmlns:scoro="http://purl.org/spar/scoro/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:biomodel="http://biomodels.net/model-qualifiers/">
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:title>Tham, Wang, Soo, Lee, Lee, Yong, Goh, Holford, 2008</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <prism:keyword>tumour</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <prism:keyword>gemcitabine</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <prism:keyword>cancer</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <prism:keyword>pharmacodynamic</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <prism:keyword>PKPD</prism:keyword>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:description>

#### Model Status



 This CellML model runs in PCenv and OpenCell to recreate the published results, but not COR because of the presence of the modulo operator. The maximum step size must be constrained to be 0.001 weeks or smaller, or the software will ignore the pulsatile administration of gemcitabine. This model describes the response of tumor size to administration of gemcitabine, and was based off original Berkeley Madonna code provided by the model authors. 
 
 


#### Model Structure



ABSTRACT: PURPOSE: This tumor response pharmacodynamic model aims to describe primary lesion shrinkage in non-small cell lung cancer over time and determine if concentration-based exposure metrics for gemcitabine or that of its metabolites, 2',2'-difluorodeoxyuridine or gemcitabine triphosphate, are better than gemcitabine dose for prediction of individual response. EXPERIMENTAL DESIGN: Gemcitabine was given thrice weekly on days 1 and 8 in combination with carboplatin, which was given only on day 1 of every cycle. Gemcitabine amount in the body and area under the concentration-time curves of plasma gemcitabine, 2',2'-difluorodeoxyuridine, and intracellular gemcitabine triphosphate in white cells were compared to determine which best describes tumor shrinkage over time. Tumor growth kinetics were described using a Gompertz-like model. RESULTS: The apparent half-life for the effect of gemcitabine was 7.67 weeks. The tumor turnover time constant was 21.8 week.cm. Baseline tumor size and gemcitabine amount in the body to attain 50% of tumor shrinkage were estimated to be 6.66 cm and 10,600 mg. There was no evidence of relapse during treatment. CONCLUSIONS: Concentration-based exposure metrics for gemcitabine and its metabolites were no better than gemcitabine amount in predicting tumor shrinkage in primary lung cancer lesions. Gemcitabine dose-based models did marginally better than treatment-based models that ignored doses of drug administered to patients. Modeling tumor shrinkage in primary lesions can be used to quantify individual sensitivity and response to antitumor effects of anticancer drugs.




The original paper reference is cited below:




A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients, Lai-San Tham, Lingzhi Wang, Ross A Soo, Soo-Chin Lee, How-Sung Lee, Wei-Peng Yong, Boon-Cher Goh and Nicholas H.G. Holford, 2008, *Clin Cancer Res*, volume 14, 4213-4218. [PubMed ID: 18594002](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=18594002&amp;query_hl=1&amp;itool=pubmed_docsum)





|  |
| --- |
|  |
| Schematic diagram of the model. |



</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <collex:thumbnail rdf:resource="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.png">http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <rdfs:label>Lai-San Tham</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <foaf:name>Lai-San Tham</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00001">local:00001</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <rdfs:label>Lingzhi Wang</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00002">
    <foaf:name>Lingzhi Wang</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00002">local:00002</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <rdfs:label>Ross A. Soo</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00003">
    <foaf:name>Ross A. Soo</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00003">local:00003</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <rdfs:label>Soo-Chin Lee</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00004">
    <foaf:name>Soo-Chin Lee</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00004">local:00004</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <rdfs:label>How-Sung Lee</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00005">
    <foaf:name>How-Sung Lee</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00005">local:00005</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <rdfs:label>Wei-Peng Yong</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00006">
    <foaf:name>Wei-Peng Yong</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00006">local:00006</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <rdfs:label>Boon-Cher Goh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00007">
    <foaf:name>Boon-Cher Goh</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00007">local:00007</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <rdfs:label>Nicholas H.G. Holford</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00008">
    <foaf:name>Nicholas H.G. Holford</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:creator rdf:resource="local:00008">local:00008</dc:creator>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <dc:identifier rdf:resource="http://identifiers.org/orcid:0000-0001-5801-5510">http://identifiers.org/orcid:0000-0001-5801-5510</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <rdfs:label>Bilal Shaikh</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <foaf:accountName rdf:resource="https://orcid.org/0000-0001-5801-5510">https://orcid.org/0000-0001-5801-5510</foaf:accountName>
  </rdf:Description>
  <rdf:Description rdf:about="local:00009">
    <foaf:name>Bilal Shaikh</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:contributor rdf:resource="local:00009">local:00009</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <rdfs:label>Geoff Nunns</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="local:00010">
    <foaf:name>Geoff Nunns</foaf:name>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:contributor rdf:resource="local:00010">local:00010</dc:contributor>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <dc:identifier rdf:resource="https://identifiers.org/pmr:1985e7c820ff102b1caebc241df65ce7">https://identifiers.org/pmr:1985e7c820ff102b1caebc241df65ce7</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00011">
    <rdfs:label>PMR: 1985e7c820ff102b1caebc241df65ce7</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <bqmodel:is rdf:resource="local:00011">local:00011</bqmodel:is>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <dc:identifier rdf:resource="https://identifiers.org/doi/10.1158/1078-0432.CCR-07-4754">https://identifiers.org/doi/10.1158/1078-0432.CCR-07-4754</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00012">
    <rdfs:label>Lai-San Tham, Lingzhi Wang, Ross A. Soo, Soo-Chin Lee, How-Sung Lee, Wei-Peng Yong, Boon-Cher Goh &amp; Nicholas H.G. Holford. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clinical Cancer Research 14, 13: 4213-4218 (2008).</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00012">local:00012</bqmodel:isDescribedBy>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00013">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex">
    <dc:license rdf:resource="local:00013">local:00013</dc:license>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.cellml">
    <dc:title>A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients</dc:title>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.cellml">
    <dc:description>

#### Model Status



 This CellML model runs in PCenv and OpenCell to recreate the published results, but not COR because of the presence of the modulo operator. The maximum step size must be constrained to be 0.001 weeks or smaller, or the software will ignore the pulsatile administration of gemcitabine. This model describes the response of tumor size to administration of gemcitabine, and was based off original Berkeley Madonna code provided by the model authors. 
 
 


#### Model Structure



ABSTRACT: PURPOSE: This tumor response pharmacodynamic model aims to describe primary lesion shrinkage in non-small cell lung cancer over time and determine if concentration-based exposure metrics for gemcitabine or that of its metabolites, 2',2'-difluorodeoxyuridine or gemcitabine triphosphate, are better than gemcitabine dose for prediction of individual response. EXPERIMENTAL DESIGN: Gemcitabine was given thrice weekly on days 1 and 8 in combination with carboplatin, which was given only on day 1 of every cycle. Gemcitabine amount in the body and area under the concentration-time curves of plasma gemcitabine, 2',2'-difluorodeoxyuridine, and intracellular gemcitabine triphosphate in white cells were compared to determine which best describes tumor shrinkage over time. Tumor growth kinetics were described using a Gompertz-like model. RESULTS: The apparent half-life for the effect of gemcitabine was 7.67 weeks. The tumor turnover time constant was 21.8 week.cm. Baseline tumor size and gemcitabine amount in the body to attain 50% of tumor shrinkage were estimated to be 6.66 cm and 10,600 mg. There was no evidence of relapse during treatment. CONCLUSIONS: Concentration-based exposure metrics for gemcitabine and its metabolites were no better than gemcitabine amount in predicting tumor shrinkage in primary lung cancer lesions. Gemcitabine dose-based models did marginally better than treatment-based models that ignored doses of drug administered to patients. Modeling tumor shrinkage in primary lesions can be used to quantify individual sensitivity and response to antitumor effects of anticancer drugs.




The original paper reference is cited below:




A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients, Lai-San Tham, Lingzhi Wang, Ross A Soo, Soo-Chin Lee, How-Sung Lee, Wei-Peng Yong, Boon-Cher Goh and Nicholas H.G. Holford, 2008, *Clin Cancer Res*, volume 14, 4213-4218. [PubMed ID: 18594002](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=18594002&amp;query_hl=1&amp;itool=pubmed_docsum)





|  |
| --- |
|  |
| Schematic diagram of the model. |




</dc:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.cellml">
    <collex:thumbnail rdf:resource="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.png">http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.png</collex:thumbnail>
  </rdf:Description>
  <rdf:Description rdf:about="local:00014">
    <dc:identifier rdf:resource="https://creativecommons.org/licenses/by/3.0/">https://creativecommons.org/licenses/by/3.0/</dc:identifier>
  </rdf:Description>
  <rdf:Description rdf:about="local:00014">
    <rdfs:label>CC BY 3.0</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="http://omex-library.org/1985e7c820ff102b1caebc241df65ce7.omex/tham_2008.cellml">
    <dc:license rdf:resource="local:00014">local:00014</dc:license>
  </rdf:Description>
</rdf:RDF>
